Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-08-30
2011-08-30
Bristol, Lynn (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007250
Reexamination Certificate
active
08008022
ABSTRACT:
The present inventions relates to kits and methods for diagnosing and monitoring breast cancer. An increase in the level or activity of proteins of the ubiquitin/proteasome pathway, and ancillary proteins thereof, as compared to normal control or benign tissue is indicative of breast cancer.
REFERENCES:
patent: 5744343 (1998-04-01), Draetta et al.
patent: 2006/0234287 (2006-10-01), Erlander et al.
Stanton, P et al, 1994, Br J Cancer, 70: 427-433.
Iehle, C et al, 1999, J Steroid Biochem Mol Biol, 68: 189-195.
Abbaszadegan, M R, et al, 1994, Cancer Res, 54: 4676-4679.
Bowie (Science, 1990, 257:1306-1310).
Geng et al, Cellular and molecular immunology (China), 2006, 3 (6), p. 439-43.
Dapas et al., “Identification of different isoforms of eEF1A in the nuclear fraction of human T-lymphoblastic cancer cell line specifically binding to aptameric cytotoxic GT oligomers”, Eur. J. Biochem. 2003 270:3251-3262.
Dragnev et al., “Specific Chemopreventive Agents Trigger Proteasomal Degradation of G1 Cyclins: Implications for Combination Therapy”, Clinical Cancer Research 2004 (10):2570-2577.
Lamberti et al., “The translation elongation factr 1A in tumorigenesis, signal transduction and apoptosis:Review article”, Amino Acids 2004 26:443-448.
Ohta et al., “Ubiquitin and breast cancer”, Oncogene 2004 23:2079-2088.
Rossi et al., “The role of the ubiquitination-proteasome pathway in breast cancer Use of mouse models for analyzing ubiquitination processes”, Breast Cancer Research 2003 5(1):16-22.
Ruffner et al., “Cancer-predisposing mutations within the RING domain of BRCA1:Loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity”, Proc. Natl. Acad. Sci. USA 2001 98(8):5134-5139.
Thompson et al., “p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells”, Oncogene 2003 22:2322-2333.
Voorhees et al., “The Proteasome as a Target for Cancer Therapy”, Clinical Cancer Research 2003 9:6316-6325.
Wyke et al., “Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation”, British Journal of Cancer 2004 91:1742-1750.
Yang et al., “Cancer Chemoprevention by Targeting Proteasomal Degradation”, Commentary re KA Dragnev et al, Specific Chemopreventive Agents Trigger Proteasomal Degradation of G1 Cyclins:Implications for Combination Therapy, Clin Cancer Res. 2004 10:2570-2577.
Zhang et al., “Inhibitory effect of ubiquitin-proteasome pathway on proliferation of esophageal carcinoma cells”, World J. Gastroenterol. 2004 10:2779-2784.
Chen Li
Madura Kiran
Bristol Lynn
Licata & Tyrrell P.C.
University of Medicine and Dentistry of New Jersey
LandOfFree
Methods and kit for detecting breast cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and kit for detecting breast cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and kit for detecting breast cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2671225